Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
Fiche publication
Date publication
octobre 2023
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Westeel V, Schuette W, Urban T, Radonjic D, von Wangenheim U, Lorence RM, Reck M
Lien Pubmed
Résumé
Studies have shown improved tolerability with once-weekly versus three-weekly docetaxel in the second-line treatment of advanced non-small cell lung cancer (NSCLC). This study aimed to evaluate the tolerability of nintedanib plus weekly docetaxel in patients with NSCLC.
Référence
PLoS One. 2023 10 17;18(10):e0292307